PCV81 AN ECONOMIC EVALUATION OF THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY IN TERMS OF OPTIMAL LIPID VALUE ATTAINMENT
Abstract
Authors
S Balu RJ Simko RT Burge MJ Cziraky RA Quimbo